Home Healthcare Pharmaceuticals Glioblastoma Multiforme (GBM) Treatment Market

Glioblastoma Multiforme (GBM) Treatment Market Size, Share & Trends Analysis Report By Treatment (Surgery, Radiation Therapy, Chemotherapy, Targeted Therapy, Tumor Treating Field (TTF) Therapy, Immunotherapy), By Drugs (Temozolomide, Bevacizumab, Lomustine, Carmustine Wafers, Others), By End-User (Hospitals, Clinics, Ambulatory Surgical Centers) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: May 25, 2026 | Author: Debashree B | Format: | Report Code: SR4657DR | Pages: 155
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. Glioblastoma Multiforme (GBM) Treatment Market, By Treatment 2022-2034 (USD MILLION/ Units)
    1. Surgery
    2. Radiation Therapy
    3. Chemotherapy
    4. Targeted Therapy
    5. Tumor Treating Field (TTF) Therapy
    6. Immunotherapy
  2. Glioblastoma Multiforme (GBM) Treatment Market, By Drugs 2022-2034 (USD MILLION/ Units)
    1. Temozolomide
    2. Bevacizumab
    3. Lomustine
    4. Carmustine Wafers
    5. Others
  3. Glioblastoma Multiforme (GBM) Treatment Market, By End-User 2022-2034 (USD MILLION/ Units)
    1. Hospitals
    2. Clinics
    3. Ambulatory Surgical Centers
  4. Regional Glioblastoma Multiforme (GBM) Treatment Market
    1. North America
      1. North America Glioblastoma Multiforme (GBM) Treatment Market By Treatment 2022-2034 (USD MILLION/ Units)
        1. Surgery
        2. Radiation Therapy
        3. Chemotherapy
        4. Targeted Therapy
        5. Tumor Treating Field (TTF) Therapy
        6. Immunotherapy
      2. North America Glioblastoma Multiforme (GBM) Treatment Market By Drugs 2022-2034 (USD MILLION/ Units)
        1. Temozolomide
        2. Bevacizumab
        3. Lomustine
        4. Carmustine Wafers
        5. Others
      3. North America Glioblastoma Multiforme (GBM) Treatment Market By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Clinics
        3. Ambulatory Surgical Centers
      4. U.S.
        1. Surgery
        2. Radiation Therapy
        3. Chemotherapy
        4. Targeted Therapy
        5. Tumor Treating Field (TTF) Therapy
        6. Immunotherapy
        7. Temozolomide
        8. Bevacizumab
        9. Lomustine
        10. Carmustine Wafers
        11. Others
        12. Hospitals
        13. Clinics
        14. Ambulatory Surgical Centers
      5. Canada
        1. Surgery
        2. Radiation Therapy
        3. Chemotherapy
        4. Targeted Therapy
        5. Tumor Treating Field (TTF) Therapy
        6. Immunotherapy
        7. Temozolomide
        8. Bevacizumab
        9. Lomustine
        10. Carmustine Wafers
        11. Others
        12. Hospitals
        13. Clinics
        14. Ambulatory Surgical Centers
    2. Europe
      1. Europe Glioblastoma Multiforme (GBM) Treatment Market By Treatment 2022-2034 (USD MILLION/ Units)
        1. Surgery
        2. Radiation Therapy
        3. Chemotherapy
        4. Targeted Therapy
        5. Tumor Treating Field (TTF) Therapy
        6. Immunotherapy
      2. Europe Glioblastoma Multiforme (GBM) Treatment Market By Drugs 2022-2034 (USD MILLION/ Units)
        1. Temozolomide
        2. Bevacizumab
        3. Lomustine
        4. Carmustine Wafers
        5. Others
      3. Europe Glioblastoma Multiforme (GBM) Treatment Market By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Clinics
        3. Ambulatory Surgical Centers
      4. U.K.
        1. Surgery
        2. Radiation Therapy
        3. Chemotherapy
        4. Targeted Therapy
        5. Tumor Treating Field (TTF) Therapy
        6. Immunotherapy
        7. Temozolomide
        8. Bevacizumab
        9. Lomustine
        10. Carmustine Wafers
        11. Others
        12. Hospitals
        13. Clinics
        14. Ambulatory Surgical Centers
      5. Germany
        1. Surgery
        2. Radiation Therapy
        3. Chemotherapy
        4. Targeted Therapy
        5. Tumor Treating Field (TTF) Therapy
        6. Immunotherapy
        7. Temozolomide
        8. Bevacizumab
        9. Lomustine
        10. Carmustine Wafers
        11. Others
        12. Hospitals
        13. Clinics
        14. Ambulatory Surgical Centers
      6. France
        1. Surgery
        2. Radiation Therapy
        3. Chemotherapy
        4. Targeted Therapy
        5. Tumor Treating Field (TTF) Therapy
        6. Immunotherapy
        7. Temozolomide
        8. Bevacizumab
        9. Lomustine
        10. Carmustine Wafers
        11. Others
        12. Hospitals
        13. Clinics
        14. Ambulatory Surgical Centers
      7. Spain
        1. Surgery
        2. Radiation Therapy
        3. Chemotherapy
        4. Targeted Therapy
        5. Tumor Treating Field (TTF) Therapy
        6. Immunotherapy
        7. Temozolomide
        8. Bevacizumab
        9. Lomustine
        10. Carmustine Wafers
        11. Others
        12. Hospitals
        13. Clinics
        14. Ambulatory Surgical Centers
      8. Italy
        1. Surgery
        2. Radiation Therapy
        3. Chemotherapy
        4. Targeted Therapy
        5. Tumor Treating Field (TTF) Therapy
        6. Immunotherapy
        7. Temozolomide
        8. Bevacizumab
        9. Lomustine
        10. Carmustine Wafers
        11. Others
        12. Hospitals
        13. Clinics
        14. Ambulatory Surgical Centers
      9. Russia
        1. Surgery
        2. Radiation Therapy
        3. Chemotherapy
        4. Targeted Therapy
        5. Tumor Treating Field (TTF) Therapy
        6. Immunotherapy
        7. Temozolomide
        8. Bevacizumab
        9. Lomustine
        10. Carmustine Wafers
        11. Others
        12. Hospitals
        13. Clinics
        14. Ambulatory Surgical Centers
      10. Nordic
        1. Surgery
        2. Radiation Therapy
        3. Chemotherapy
        4. Targeted Therapy
        5. Tumor Treating Field (TTF) Therapy
        6. Immunotherapy
        7. Temozolomide
        8. Bevacizumab
        9. Lomustine
        10. Carmustine Wafers
        11. Others
        12. Hospitals
        13. Clinics
        14. Ambulatory Surgical Centers
      11. Benelux
        1. Surgery
        2. Radiation Therapy
        3. Chemotherapy
        4. Targeted Therapy
        5. Tumor Treating Field (TTF) Therapy
        6. Immunotherapy
        7. Temozolomide
        8. Bevacizumab
        9. Lomustine
        10. Carmustine Wafers
        11. Others
        12. Hospitals
        13. Clinics
        14. Ambulatory Surgical Centers
      12. Rest of Europe
        1. Surgery
        2. Radiation Therapy
        3. Chemotherapy
        4. Targeted Therapy
        5. Tumor Treating Field (TTF) Therapy
        6. Immunotherapy
        7. Temozolomide
        8. Bevacizumab
        9. Lomustine
        10. Carmustine Wafers
        11. Others
        12. Hospitals
        13. Clinics
        14. Ambulatory Surgical Centers
    3. APAC
      1. APAC Glioblastoma Multiforme (GBM) Treatment Market By Treatment 2022-2034 (USD MILLION/ Units)
        1. Surgery
        2. Radiation Therapy
        3. Chemotherapy
        4. Targeted Therapy
        5. Tumor Treating Field (TTF) Therapy
        6. Immunotherapy
      2. APAC Glioblastoma Multiforme (GBM) Treatment Market By Drugs 2022-2034 (USD MILLION/ Units)
        1. Temozolomide
        2. Bevacizumab
        3. Lomustine
        4. Carmustine Wafers
        5. Others
      3. APAC Glioblastoma Multiforme (GBM) Treatment Market By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Clinics
        3. Ambulatory Surgical Centers
      4. China
        1. Surgery
        2. Radiation Therapy
        3. Chemotherapy
        4. Targeted Therapy
        5. Tumor Treating Field (TTF) Therapy
        6. Immunotherapy
        7. Temozolomide
        8. Bevacizumab
        9. Lomustine
        10. Carmustine Wafers
        11. Others
        12. Hospitals
        13. Clinics
        14. Ambulatory Surgical Centers
      5. Korea
        1. Surgery
        2. Radiation Therapy
        3. Chemotherapy
        4. Targeted Therapy
        5. Tumor Treating Field (TTF) Therapy
        6. Immunotherapy
        7. Temozolomide
        8. Bevacizumab
        9. Lomustine
        10. Carmustine Wafers
        11. Others
        12. Hospitals
        13. Clinics
        14. Ambulatory Surgical Centers
      6. Japan
        1. Surgery
        2. Radiation Therapy
        3. Chemotherapy
        4. Targeted Therapy
        5. Tumor Treating Field (TTF) Therapy
        6. Immunotherapy
        7. Temozolomide
        8. Bevacizumab
        9. Lomustine
        10. Carmustine Wafers
        11. Others
        12. Hospitals
        13. Clinics
        14. Ambulatory Surgical Centers
      7. India
        1. Surgery
        2. Radiation Therapy
        3. Chemotherapy
        4. Targeted Therapy
        5. Tumor Treating Field (TTF) Therapy
        6. Immunotherapy
        7. Temozolomide
        8. Bevacizumab
        9. Lomustine
        10. Carmustine Wafers
        11. Others
        12. Hospitals
        13. Clinics
        14. Ambulatory Surgical Centers
      8. Australia
        1. Surgery
        2. Radiation Therapy
        3. Chemotherapy
        4. Targeted Therapy
        5. Tumor Treating Field (TTF) Therapy
        6. Immunotherapy
        7. Temozolomide
        8. Bevacizumab
        9. Lomustine
        10. Carmustine Wafers
        11. Others
        12. Hospitals
        13. Clinics
        14. Ambulatory Surgical Centers
      9. Taiwan
        1. Surgery
        2. Radiation Therapy
        3. Chemotherapy
        4. Targeted Therapy
        5. Tumor Treating Field (TTF) Therapy
        6. Immunotherapy
        7. Temozolomide
        8. Bevacizumab
        9. Lomustine
        10. Carmustine Wafers
        11. Others
        12. Hospitals
        13. Clinics
        14. Ambulatory Surgical Centers
      10. South East Asia
        1. Surgery
        2. Radiation Therapy
        3. Chemotherapy
        4. Targeted Therapy
        5. Tumor Treating Field (TTF) Therapy
        6. Immunotherapy
        7. Temozolomide
        8. Bevacizumab
        9. Lomustine
        10. Carmustine Wafers
        11. Others
        12. Hospitals
        13. Clinics
        14. Ambulatory Surgical Centers
      11. Rest of Asia-Pacific
        1. Surgery
        2. Radiation Therapy
        3. Chemotherapy
        4. Targeted Therapy
        5. Tumor Treating Field (TTF) Therapy
        6. Immunotherapy
        7. Temozolomide
        8. Bevacizumab
        9. Lomustine
        10. Carmustine Wafers
        11. Others
        12. Hospitals
        13. Clinics
        14. Ambulatory Surgical Centers
    4. Middle East and Africa
      1. Middle East and Africa Glioblastoma Multiforme (GBM) Treatment Market By Treatment 2022-2034 (USD MILLION/ Units)
        1. Surgery
        2. Radiation Therapy
        3. Chemotherapy
        4. Targeted Therapy
        5. Tumor Treating Field (TTF) Therapy
        6. Immunotherapy
      2. Middle East and Africa Glioblastoma Multiforme (GBM) Treatment Market By Drugs 2022-2034 (USD MILLION/ Units)
        1. Temozolomide
        2. Bevacizumab
        3. Lomustine
        4. Carmustine Wafers
        5. Others
      3. Middle East and Africa Glioblastoma Multiforme (GBM) Treatment Market By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Clinics
        3. Ambulatory Surgical Centers
      4. UAE
        1. Surgery
        2. Radiation Therapy
        3. Chemotherapy
        4. Targeted Therapy
        5. Tumor Treating Field (TTF) Therapy
        6. Immunotherapy
        7. Temozolomide
        8. Bevacizumab
        9. Lomustine
        10. Carmustine Wafers
        11. Others
        12. Hospitals
        13. Clinics
        14. Ambulatory Surgical Centers
      5. Turkey
        1. Surgery
        2. Radiation Therapy
        3. Chemotherapy
        4. Targeted Therapy
        5. Tumor Treating Field (TTF) Therapy
        6. Immunotherapy
        7. Temozolomide
        8. Bevacizumab
        9. Lomustine
        10. Carmustine Wafers
        11. Others
        12. Hospitals
        13. Clinics
        14. Ambulatory Surgical Centers
      6. Saudi Arabia
        1. Surgery
        2. Radiation Therapy
        3. Chemotherapy
        4. Targeted Therapy
        5. Tumor Treating Field (TTF) Therapy
        6. Immunotherapy
        7. Temozolomide
        8. Bevacizumab
        9. Lomustine
        10. Carmustine Wafers
        11. Others
        12. Hospitals
        13. Clinics
        14. Ambulatory Surgical Centers
      7. South Africa
        1. Surgery
        2. Radiation Therapy
        3. Chemotherapy
        4. Targeted Therapy
        5. Tumor Treating Field (TTF) Therapy
        6. Immunotherapy
        7. Temozolomide
        8. Bevacizumab
        9. Lomustine
        10. Carmustine Wafers
        11. Others
        12. Hospitals
        13. Clinics
        14. Ambulatory Surgical Centers
      8. Egypt
        1. Surgery
        2. Radiation Therapy
        3. Chemotherapy
        4. Targeted Therapy
        5. Tumor Treating Field (TTF) Therapy
        6. Immunotherapy
        7. Temozolomide
        8. Bevacizumab
        9. Lomustine
        10. Carmustine Wafers
        11. Others
        12. Hospitals
        13. Clinics
        14. Ambulatory Surgical Centers
      9. Nigeria
        1. Surgery
        2. Radiation Therapy
        3. Chemotherapy
        4. Targeted Therapy
        5. Tumor Treating Field (TTF) Therapy
        6. Immunotherapy
        7. Temozolomide
        8. Bevacizumab
        9. Lomustine
        10. Carmustine Wafers
        11. Others
        12. Hospitals
        13. Clinics
        14. Ambulatory Surgical Centers
      10. Rest of MEA
        1. Surgery
        2. Radiation Therapy
        3. Chemotherapy
        4. Targeted Therapy
        5. Tumor Treating Field (TTF) Therapy
        6. Immunotherapy
        7. Temozolomide
        8. Bevacizumab
        9. Lomustine
        10. Carmustine Wafers
        11. Others
        12. Hospitals
        13. Clinics
        14. Ambulatory Surgical Centers
    5. LATAM
      1. LATAM Glioblastoma Multiforme (GBM) Treatment Market By Treatment 2022-2034 (USD MILLION/ Units)
        1. Surgery
        2. Radiation Therapy
        3. Chemotherapy
        4. Targeted Therapy
        5. Tumor Treating Field (TTF) Therapy
        6. Immunotherapy
      2. LATAM Glioblastoma Multiforme (GBM) Treatment Market By Drugs 2022-2034 (USD MILLION/ Units)
        1. Temozolomide
        2. Bevacizumab
        3. Lomustine
        4. Carmustine Wafers
        5. Others
      3. LATAM Glioblastoma Multiforme (GBM) Treatment Market By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Clinics
        3. Ambulatory Surgical Centers
      4. Brazil
        1. Surgery
        2. Radiation Therapy
        3. Chemotherapy
        4. Targeted Therapy
        5. Tumor Treating Field (TTF) Therapy
        6. Immunotherapy
        7. Temozolomide
        8. Bevacizumab
        9. Lomustine
        10. Carmustine Wafers
        11. Others
        12. Hospitals
        13. Clinics
        14. Ambulatory Surgical Centers
      5. Mexico
        1. Surgery
        2. Radiation Therapy
        3. Chemotherapy
        4. Targeted Therapy
        5. Tumor Treating Field (TTF) Therapy
        6. Immunotherapy
        7. Temozolomide
        8. Bevacizumab
        9. Lomustine
        10. Carmustine Wafers
        11. Others
        12. Hospitals
        13. Clinics
        14. Ambulatory Surgical Centers
      6. Argentina
        1. Surgery
        2. Radiation Therapy
        3. Chemotherapy
        4. Targeted Therapy
        5. Tumor Treating Field (TTF) Therapy
        6. Immunotherapy
        7. Temozolomide
        8. Bevacizumab
        9. Lomustine
        10. Carmustine Wafers
        11. Others
        12. Hospitals
        13. Clinics
        14. Ambulatory Surgical Centers
      7. Chile
        1. Surgery
        2. Radiation Therapy
        3. Chemotherapy
        4. Targeted Therapy
        5. Tumor Treating Field (TTF) Therapy
        6. Immunotherapy
        7. Temozolomide
        8. Bevacizumab
        9. Lomustine
        10. Carmustine Wafers
        11. Others
        12. Hospitals
        13. Clinics
        14. Ambulatory Surgical Centers
      8. Colombia
        1. Surgery
        2. Radiation Therapy
        3. Chemotherapy
        4. Targeted Therapy
        5. Tumor Treating Field (TTF) Therapy
        6. Immunotherapy
        7. Temozolomide
        8. Bevacizumab
        9. Lomustine
        10. Carmustine Wafers
        11. Others
        12. Hospitals
        13. Clinics
        14. Ambulatory Surgical Centers
      9. Rest of LATAM
        1. Surgery
        2. Radiation Therapy
        3. Chemotherapy
        4. Targeted Therapy
        5. Tumor Treating Field (TTF) Therapy
        6. Immunotherapy
        7. Temozolomide
        8. Bevacizumab
        9. Lomustine
        10. Carmustine Wafers
        11. Others
        12. Hospitals
        13. Clinics
        14. Ambulatory Surgical Centers
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.